BioMind Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
60
- Latest Deal Type
-
Series A
- Investors
-
3
BioMind General Information
Description
Developer of a healthcare diagnosis technology. The company's medical platform uses artificial intelligence technology to provide fast and accurate diagnosis assistance, covering brain tumors, vascular diseases and stroke diseases, enabling medical experts and doctors to obtain assistance in diagnosis and increase work efficiency.
Contact Information
Website
www.biomind.aiCorporate Office
- 8th Floor, No. 10 Anxiang Road
- Linkong Economic Core District, Shunyi District
- Beijing
- China
Corporate Office
- 8th Floor, No. 10 Anxiang Road
- Linkong Economic Core District, Shunyi District
- Beijing
- China
BioMind Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 01-Aug-2019 | Completed | Generating Revenue | |||
| 1. Joint Venture | 01-Jan-2017 | Completed | Generating Revenue |
BioMind Comparisons
Industry
Financing
Details
BioMind Competitors (3)
One of BioMind’s 3 competitors is Infermedica, a Venture Capital-Backed company based in Wroclaw, Poland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Infermedica | Venture Capital-Backed | Wroclaw, Poland | ||||
| Yizhun AI | Venture Capital-Backed | Beijing, China | ||||
| Hindsait | Venture Capital-Backed | Hackensack, NJ |
BioMind Patents
BioMind Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026108090-A1 | Multi-volume series image data processing method, computer device, and readable storage medium | Pending | 22-Nov-2024 | ||
| WO-2026108089-A1 | Vascular stenosis rate prediction method, prediction model and prediction system | Pending | 22-Nov-2024 | ||
| WO-2026007502-A1 | Processing method and apparatus for predicting aspects on basis of ct images | Pending | 01-Jul-2024 | ||
| WO-2025223404-A1 | Ct image-based t-stage classification prediction processing method and apparatus | Pending | 26-Apr-2024 | ||
| WO-2025223405-A1 | N-stage classification prediction processing method and apparatus based on ct image | Pending | 26-Apr-2024 | G06V10/764 |
BioMind Signals
BioMind Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CAS Investment Management | Growth/Expansion | Minority | ||
| Hanalytics | Other | Minority | ||
| Tiantan Hospital | University | Majority |
BioMind FAQs
-
When was BioMind founded?
BioMind was founded in 2017.
-
Where is BioMind headquartered?
BioMind is headquartered in Beijing, China.
-
What is the size of BioMind?
BioMind has 60 total employees.
-
What industry is BioMind in?
BioMind’s primary industry is Decision/Risk Analysis.
-
Is BioMind a private or public company?
BioMind is a Private company.
-
What is the current valuation of BioMind?
The current valuation of BioMind is .
-
What is BioMind’s current revenue?
The current revenue for BioMind is .
-
Who are BioMind’s investors?
CAS Investment Management, Hanalytics, and Tiantan Hospital have invested in BioMind.
-
Who are BioMind’s competitors?
Infermedica, Yizhun AI, and Hindsait are competitors of BioMind.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process